Aker BioMarine Plans US NDI Notification For EPA/DHA Formulated To Pass Blood-Brain Barrier
Executive Summary
Aker BioMarine seeks supplement firms to use its EPA/DHA innovation bound by lysophosphatidylcholine to enable the fatty acids to pass through the blood-brain and blood-retinal barriers and boost of eye and brain health benefits. It will submit an NDI notificaion in the US during 2022.
You may also be interested in...
HBW US Executive Decisions: CRN Communications Director, GNC Science And People Chiefs
Aker BioMarine provides krill oil for e-sports team Heroic to reach market with “massive growth in recent years”; award-winning public relations strategist Craig Muckle joins CRN; and GNC names chief science and chief people officers.
In US, Market Exclusivity For NDI Notifications ‘Just Not There’ In DSHEA Regulation
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.
Framework To Protect NDI Notifications With Master Files Proposed By CHPA, CRN And UNPA
Consumer Healthcare Products Association, Council for Responsible Nutrition and United Natural Products Alliance model proposed NDI-master file framework on US Drug Master File FDA has accepted for decades. System would not be administered by FDA, but the agency’s support is critical for helping manufacturers protect their investments in research for information supporting NDI notifications.